CDK9 and posterior cortical atrophy: While it is highly unlikely that monotherapy with CDK9 inhibitors can completely suppress the metastatic progression of PCa after ARSi, our study provides a proof of concept for the future exploration of combination treatment strategies, particularly focusing on targeting AR-V7 phosphorylation early to prevent PCa cells from initiating more aggressive metastatic progress in bone.